NCT04206787

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Real-world Study on Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer (NSCLC)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 72 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to observe the sequential strategy with afatinib as first-line treatment and to find the optimal treatment strategy for long-term chemotherapy-free regimens in Chinese patients with EGFR-mutated advanced NSCLC. Furthermore, this study can also assess the effectiveness and safety of afatinib as first-line treatment.

Conditions

• Non-squamous, Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Afatinib	drug

Timeline

• Start date: 2020-05-20
• Primary completion: 2023-12-18
• Completion: 2023-12-22
• First posted: 2019-12-20
• Last updated: 2025-02-28
• Results posted: 2025-02-28

Locations

10 sites across 1 country: China